Genentech Files sBLA for Avastin for First-Line NSCLC Treatment

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 5
Volume 15
Issue 5

Genentech Files sBLA for Avastin for First-Line NSCLC Treatment

SOUTH SAN FRANCISCO—Genentech Inc. has submitted a supplemental Biologics License Application (sBLA) to FDA for bevacizumab (Avastin) in combination with platinum-based chemotherapy for first-line treatment of advanced, non-squamous, non-small-cell lung cancer (NSCLC). The company has requested priority review on the submission. In a phase III trial (E4599) in patients with locally advanced, metastatic, or recurrent NSCLC, Avastin plus paclitaxel and carboplatin improved overall survival by 25%, compared with chemotherapy alone.

Recent Videos
Video 4 - "Frontline Treatment for EGFR-Mutated Lung Cancer"
Video 3 - "NGS Testing Challenges and Considerations in NSCLC"
Related Content